Excellent response to rituximab in a patient with recalcitrant epidermolysis bullosa acquisita: a case report

Epidermolysis Bullosa Acquisita is a rare, chronic autoimmune blistering disorder characterized by vesicles and bullae on the skin and mucous membranes. This condition, presenting typically in adulthood, is caused by autoantibodies against type VII collagen. Conventional treatments, including system...

Full description

Bibliographic Details
Published in:Journal of the Egyptian Women’s Dermatologic Society
Main Authors: Fahad Alrashidi, Khalid Nabil Nagshabandi, Ruaa Alharithy
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-05-01
Subjects:
biologics
epidermolysis bullosa acquisita
rituximab
Online Access:https://journals.lww.com/10.4103/jewd.jewd_109_24
Description
Summary:Epidermolysis Bullosa Acquisita is a rare, chronic autoimmune blistering disorder characterized by vesicles and bullae on the skin and mucous membranes. This condition, presenting typically in adulthood, is caused by autoantibodies against type VII collagen. Conventional treatments, including systemic corticosteroids and immunosuppressants, often fail to achieve long-term remission. Biologic agents like rituximab have shown promise in managing refractory cases. This report presents a case of a 27-year-old female with recalcitrant epidermolysis bullosa acquisita successfully managed after starting rituximab therapy.
ISSN:2090-2565

Similar Items